Drug Topics

JUNE 9, 2025

News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv

FDA 282

FDA Specialty Pharmacies Compounding Independent Pharmacies 282

PharmaVoice

JUNE 9, 2025

Skip to main content CONTINUE TO SITE ➞ Dont miss the most important voices in pharma Let PharmaVoices free newsletter keep you informed on what industry leaders are saying, straight from your inbox. By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercialization Leadership Manufacturing Patient Pharma Policy & Regulation Research & Deve

147

147

Drug Topics

JUNE 9, 2025

News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv

Community Pharmacies 247

Community Pharmacies Immunization Specialty Pharmacies Compounding 247

Fierce Pharma

JUNE 9, 2025

The drug is the first triple-combo pill for the initial treatment of hypertension in the U.S.

90

90

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

JUNE 9, 2025

Hepatitis B and liver functions have been found to be independent risk factors for gestational diabetes and are found to have the highest prevalence of abnormalities.

316

316

Pharmacy Times

JUNE 9, 2025

A multidisciplinary team enhances psychiatric care by empowering community pharmacists to administer long-acting injectable antipsychotics, improving patient adherence and outcomes.

73

73

Pharmacy Times

JUNE 9, 2025

As policy developments unfold rapidly at both the state and federal levels, Tom Kraus highlights the expanding scope of pharmacist practice through a wave of state-level legislation as a key opportunity.

73

73

pharmaphorum

JUNE 9, 2025

Otsuka and Vera both have new phase 3 data on drugs for kidney disease IgA nephropathy, but can they make a mark in an increasingly crowded market

71

71

Pharmacy Times

JUNE 9, 2025

Cilta-cel shows promise as a CAR T-cell therapy, offering long-term remission for relapsed/refractory multiple myeloma patients without maintenance treatment.

81

81

STAT

JUNE 9, 2025

Health secretary Robert F. Kennedy Jr. has taken the extraordinary step of firing the expert panel that advises the Centers for Disease Control and Prevention, saying the action is needed to restore faith in vaccines. “A clean sweep is needed to re-establish public confidence in vaccine science,” Kennedy said in an op-ed published Monday afternoon in the Wall Street Journal.

Vaccines 145

Vaccines 145

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Fierce Pharma

JUNE 9, 2025

The Department of Health and Human Services has removed all 17 sitting members of the CDC's Advisory Committee on Immunization Practices.

Immunization 96

Immunization 96

STAT

JUNE 9, 2025

The National Institutes of Health has, for now, walked back a policy requiring universities and other research institutes to certify that they do not have unlawful diversity, equity, and inclusion programs or boycotts of Israel in order to receive research dollars.  The rule, which was initially posted in April , was seen as the next stage of using research funds as leverage against private universities and efforts to increase diversity in the sciences.

142

142

pharmaphorum

JUNE 9, 2025

The NHS is said to be in line for a £30bn increase to its budget in the upcoming spending review, but some are concerned it will not be enough

101

101

Pharmaceutical Technology

JUNE 9, 2025

The EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.

76

76

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

JUNE 9, 2025

The Make America Healthy Again movement has a lot of the food industry on edge. Health secretary Robert F. Kennedy Jr. and his allies have made concerns about the health effects of ultra-processed foods a government priority , putting titans like PepsiCo, Kraft Heinz, and Nestlé on the defensive. But for a smaller contingent of food companies with products that align with MAHA’s vision of what a healthy diet looks like — from organic produce to emulsifier-free chocolates

Labelling 136

Labelling 136

Pharmafile

JUNE 9, 2025

Vertex Pharmaceuticals has presented new data showing the clinical and quality-of-life benefits of its cystic fibrosis (CF) therapies, particularly Alyftrek (deutivacaftor/tezacaftor/vanzacaftor). The findings, shared at the 48th European Cystic Fibrosis Conference, 4 to 7 June 2025, Milan, Italy, highlight the potential of CF transmembrane conductance regulator (CFTR) modulators to significantly improve patient outcomes.

69

69

Fierce Pharma

JUNE 9, 2025

One day before the potential FDA approval of a rival respiratory syncytial virus monoclonal antibody from Merck, Sanofi has revealed an aggressive supply effort for its RSV blockbuster Beyfortus, including a plan to begin shipping its AstraZeneca-partnered shot early in the third quarter.

FDA 72

FDA 72

Pharmafile

JUNE 9, 2025

Elgan Pharma, specialising in neonatology, and Italy-based biopharma, Chiesi Farmaceutici, have announced the dosing of the first participating infants in FIT-PIV, a phase 3 clinical study of ELGN-2112, a prospective treatment for intestinal malabsorption in preterm infants. The FIT-PIV study is expected to roll 420 infants, born 26-32 weeks and weighing at least 500g, at […] The post Study into treatment for rare condition in premature infants launches globally appeared first on Pharmafil

59

59

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

pharmaphorum

JUNE 9, 2025

As an FDA decision nears from a rival MSD drug, Sanofi is speeding up the rollout of RSV antibody Beyfortus to get ahead of this year's season

FDA 59

FDA 59

European Pharmaceutical Review

JUNE 9, 2025

The UK Government is set to announce an investment of £86 billion in next week’s Spending Review, aimed at boosting the country’s highest growth sectors, such as life sciences. The review will specify how the government is planning to invest in Britain’s renewal, which helps to drive its Plan for Change. This commitment will support a broad range of sectors, including advanced manufacturing.

Packaging 52

Packaging 52

Pharmafile

JUNE 9, 2025

21GRAMS and Havas Lynx lead the charge at the PM Society Awards for pharma marketing and healthcare communications Commenting on behalf of the judges, Carrie Kenyon from Finger Industries said: “With an important objective, to guide doctors to a realisation that they may be practising outdated medicine in treating hyperkalaemia, the film itself was brilliantly […] The post The unbearable lightness of creativity appeared first on Pharmafile.

Communication 59

Communication 59

The Checkup by Singlecare

JUNE 9, 2025

People living with overactive bladder (OAB) are often prescribed Gemtesa , an oral tablet approved by the U.S. Food and Drug Administration (FDA) to relieve overactive bladder symptoms such as urinary incontinence. When getting a new prescription, it’s normal to wonder about possible side effects. For instance, does Gemtesa cause weight gain? The answer is no; Gemtesa isn’t associated with weight changes.

Packaging 59

Packaging FDA 59

Pharmaceutical Commerce

JUNE 9, 2025

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies 59

STAT

JUNE 9, 2025

Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial and the potential to have longer-lasting effects than current weight loss treatments on the market that are injected weekly. In one part of a Phase 1 trial where patients received a single dose, those on the highest dose of 2.4 milligrams experienced an average of 5.3% placebo-adjusted weight loss at one week, the company said Monday.

121

121

The Checkup by Singlecare

JUNE 9, 2025

In the last few years, pharmaceutical advancements have led to a new class of drugs that treat Type 2 diabetes and obesity. Known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs or GLP-1s), these medications are incredibly effective for blood sugar control and weight loss. Most GLP-1s are only FDA-approved for use in adults. However, four injectable GLP-1 drugs, Saxenda ( liraglutide ), Wegovy ( semaglutide ), Bydureon BCISE ( exenatide ), and Trulicity ( dulaglutide ), have been approve

FDA 52

FDA Hospitals 52

Pharmaceutical Technology

JUNE 9, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

FDA 52

FDA Communication Hospitals Packaging 52

pharmaphorum

JUNE 9, 2025

The EMA has become the first regulator to link the use of Novo Nordisk's GLP-1 agonist semaglutide with sight-robbing disorder NAION

113

113

Pharmaceutical Technology

JUNE 9, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

Communication 52

Communication Hospitals Packaging Insurance 52

STAT

JUNE 9, 2025

As a researcher and medical device designer, I’ve spent years immersed in pediatric hospitals and homes, observing and listening. One moment from my recent research still keeps me up at night. A mother described how her toddler stopped breathing one afternoon at home. Instead of calling 911, she grabbed a faulty suction machine, the only one Medicaid had provided and prayed it would keep working long enough to clear her son’s airway.

Hospitals 112

Hospitals 112

Fierce Pharma

JUNE 9, 2025

After questioning the benefits of checkpoint inhibitors in stomach cancer cases without PD-L1 expression, the FDA has moved to restrict the use of Merck's and Bristol Myers Squibb's immunotherapies in those patients.

FDA 95

FDA 95

STAT

JUNE 9, 2025

This is the online version of STAT’s weekly email newsletter Health Care Inc.  Sign up here. Hello, everyone! Welcome back. If you sign up for an annual STAT+ subscription in the next week, you’ll get 50% off. Appreciate all of you who choose to read us in any capacity— especially you HCI subscribers. Hit me up with your tips and summer plans: bob.herman@statnews.com.

Hospitals 109

Hospitals Documentation Insurance 109

The Checkup by Singlecare

JUNE 9, 2025

Trintellix ( vortioxetine ) is a brand-name antidepressant in the selective serotonin reuptake inhibitor /5-HT1A receptor partial agonist drug class and is an important contribution to the armamentarium of mental health prescription drugs. It is approved by the Food and Drug Administration ( FDA ) for the management of major depressive disorder ( MDD ).

FDA 52

FDA 52

Pharmaceutical Technology

JUNE 9, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

Communication 52

Communication Hospitals Packaging Insurance 52